Last reviewed · How we verify
JS207 for Injection — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
JS207 for Injection (JS207 for Injection) — Shanghai Junshi Bioscience Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| JS207 for Injection TARGET | JS207 for Injection | Shanghai Junshi Bioscience Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- JS207 for Injection CI watch — RSS
- JS207 for Injection CI watch — Atom
- JS207 for Injection CI watch — JSON
- JS207 for Injection alone — RSS
Cite this brief
Drug Landscape (2026). JS207 for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/js207-for-injection. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab